Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Healthcare Biotechnology
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by lv_426on Mar 11, 2020 12:28pm
47 Views
Post# 30793733

RE:RE:RE:RE:RE:RE:RE:WHERE DO WE GO FROM HERE

RE:RE:RE:RE:RE:RE:RE:WHERE DO WE GO FROM HERE
sammie88 wrote: People, we need to stay focused solely on the facts. The stock market has no emotion, and neither should we, when it comes to these matters. 

The past few days we have seen a wave of positive and tangiable updates, from Replicel and Shieseido; and Shiseido is a very well calculated company, they don't make statements for nothing.

Let's just wait and see what tangiable updates the coming weeks will bring. Please remain logical and contructive on this forum. It will help us all. 


But not a coordinated response from replicel and shiseido. This tells me they haven't resolved replicel failure to do a trial. They are not talking...replicel hasn't even release an official statement/news update yet.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities